Last week healthcare technology company Clarient announced the acquisition of Applied Genomics– the molecular diagnostics company developing assays for cancer diagnosis. Applied Genomics recently published their work on using five antibody test for subclassification of Lung Carcinoma. Briefly, the assay involves using a cocktail of five antibodies against proteins TRIM29, CEACAM5, SLC7A5, MUC1 in immunohistochemical testing of tissue biopsies from the patients. A score is assigned based on the result and is used to discriminate between adenocarcinoma from squamous cell carcinoma. Distinction between various subtypes of cancer is important because it helps to better target the therapy for effective treatment while minimizing the side effects. In terms of assigning score to help in cancer diagnosis this test is similar to the OVA1 test from Vermillion.
Tests developed by Applied Genomics should be of great interest to Biosensing community because of two reasons. First, the test show that multiplexing approach using panel of five antibodies is much better that two antibody panel in correctly classifying lung carcinoma. Second, the test fulfills a need for providing sensitive assays from minute amount of biological sample. Histochemical staining, the gold standard for cancer testing can’t be reliably performed on minute amount of samples obtained needle biopsies hence the need for better diagnostic testing.
Biosensors are all about providing sensitive and specific multiplexed assays from minute amount of biological sample-right?